Rose McNulty

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

Global chronic lymphocytic leukemia incidence and mortality is declining, but the disease’s prevalence has increased modestly.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Elevated levels of a combined biomarker integrating CRP, triglycerides, and glucose are associated with increased risk of rheumatoid arthritis.

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

Ryan Haumschild, PharmD, discusses overcoming barriers to cancer care access, emphasizing the role of pharmacy in improving access and affordability.

Altered expression across multiple ncRNA classes consistently correlates with inferior OS, PFS, and TTT in nearly 5000 patients.

TAM receptors could emerge as promising therapeutic targets for rheumatoid arthritis, offering insights into immune regulation and potential treatment strategies.

Higher CONUT nutritional scores strongly predict poorer survival and greater lung function decline in PPF, highlighting malnutrition as a key modifiable risk factor.

Levels of GDF15 and OPN can accurately distinguish uterine sarcoma from benign leiomyoma, with GDF15 also serving as an independent predictor of disease progression.

The algorithm could outperform existing noninvasive tools for identifying advanced fibrosis in MASH without producing indeterminate results.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

AI, especially deep learning applied to blood smear imaging, can greatly improve the speed and accuracy of leukemia detection and subtype classification.

The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.

Patients with elevated levels of multiple adipokines had the highest risk, the authors found.

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed key aspects of the KEYNOTE-B96 trial of paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

Ryan Haumschild, PharmD, MS, MBA, discusses key considerations for pharmacists to ensure access to cutting-edge therapies for patients with cancer.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

US adults with arthritis have higher odds of stress, urge, and mixed urinary incontinence, highlighting the need for routine screening and integrated care.

Early diagnosis and treatment are crucial for managing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, yet barriers hinder timely intervention.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Resmetirom improved MASH and fibrosis consistently across patients regardless of GLP-1 or SGLT2 inhibitor use, with outcomes further enhanced in those who achieved at least 5% weight loss.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths